Adverse effects of second-generation antipsychotics in children and adolescents: A bayesian meta-analysis

Journal of Clinical Psychopharmacology

Volumn 32, Issue 3, 2012, Pages 309-316

  Cohen, David ^a,b   Bonnot, Olivier ^a,b   Bodeau, Nicolas ^a   Consoli, Angèle ^a,b   Laurent, Claudine ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b CNRS   (France)

Author keywords

adolescence; adverse effects; childhood; meta analysis; second generation antipsychotics

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLESTEROL; CLOZAPINE; GLUCOSE; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; ZIPRASIDONE;

ADVERSE DRUG REACTION; AKATHISIA; ARTICLE; CHILD PSYCHIATRY; CHOLESTEROL BLOOD LEVEL; CONTROLLED CLINICAL TRIAL (TOPIC); EXTRAPYRAMIDAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOTHERAPY; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; BAYES THEOREM; CHILD; DISORDERS OF EXCESSIVE SOMNOLENCE; HUMANS; HYPERGLYCEMIA; HYPERLIPIDEMIAS; HYPERPROLACTINEMIA; WEIGHT GAIN;

EID: 84861076813     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182549259     Document Type: Article

References (62)

1. Olfson M, Blanco C, Liu L, et al. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry. 2006;63:679-685.
2. Acquaviva E, Legleye S, Auleley GR, et al. Psychotropic medication in the French child and adolescent population: Prevalence estimation from health insurance data and national self-report survey data. BMC Psychiatry. 2009;9:72.
3. Woods SW, Martin A, Spector SG, et al. Effects of development on olanzapine-associated adverse events. J Am Acad Child Adolesc Psychiatry. 2002;41:1439-1446.
4. American Diabetes Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601.
5. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302:1765-1773.
6. Bonnot O, Inaoui R, Lloret C, et al. Surveillance of metabolic syndrome, hyperprolactinemia and cardiac side effects in children and adolescent treated with antipsychotic. Actuality and recommendations. Neuropsychiatr Enfance Adolesc. 2010;58:431-438.
7. Governale L, Mehta H. Outpatient use of atypical antipsychotic agents in the pediatric population: Years 2004-2008. 2009. Available at: Http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ PediatricAdvisoryCommittee/UCM193204.pdf. Accessed July 26, 2010.
8. Cohen D. Should the use of selective serotonin reuptake inhibitors in child and adolescent depression be banned? Psychother Psychosom. 2007;76:5-14.
9. Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: Findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry. 2008;165:1420-1431.
10. Detsky AS, Naylor CD, O'Rourke K, et al. Incorporating variations in the quality of individual randomized trials into meta-analysis. J Clin Epidemiol. 1992;45:255-265.
11. Caldwell D, Ades A, Higgins J. Simultaneous comparison of multiple treatments: Combining direct and indirect evidence. BMJ. 2005;331(7521):897-900.
12. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23:3105-3124.
13. BUGS. The BUGS project. 1996-2008. Available at: Http://www.mrc-bsu.cam. ac.uk/bugs/winbugs/contents.shtml. Accessed July 28, 2010.
14. Lunn DJ, Thomas A, Best N, et al. WinBUGSVa Bayesian modelling framework: Concepts, structure, and extensibility. Stat Comput. 2000;10:325-337.
15. Casella G, George E. Explaining the Gibbs sampler. Am Stat. 1992;167-174.
16. German S, Derman D. Stochastic relaxation, Gibbs distributions and the Bayesian restoration of images. IEEE Trans Pattern Anal Machine Intell. 1984;6:721-741.
17. Metropolis N, Rosenbluth A, Teller H, et al. Equation of state calculations by fast computing machines. J Chem Physics. 1953;21:1087-1092.
18. R Development Core Team. A language and environment for statistical computing. 2010. Available at: Http://www.R-project.org. Accessed July 28, 2010.
19. Sturtz S, Ligges U, Gelman A. R2WinBUGS: A package for running WinBUGS from R. J Stat Software. 2005;12:1-16.
20. Plummer M, Best N, Cowles K, et al. CODA: Convergence diagnosis and output analysis for MCMC. R News. 2006;6:7-11.
21. Fleischhaker C, Heiser P, Hennighausen K, et al. Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents. J Neural Transm. 2007;114:273-280.
22. Ratzoni G, Gothelf D, Brand-Gothelf A, et al. Weight gain associated with olanzapine and risperidone in adolescent patients: A comparative prospective study. J Am Acad Child Adolesc Psychiatry. 2002;41:337-343.
23. Sikich L, Hamer RM, Bashford RA, et al. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: A double-blind, randomized, 8-week trial. Neuropsychopharmacology. 2004;29:133-145.
24. Findling RL, Nyilas M, Forbes RA, et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: A randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2009;70:1441-1451.
25. Haas M, Delbello MP, Pandina G, et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: A randomized, double-blind, placebo-controlled study. Bipolar Disord. 2009;11:687-700.
26. Haas M, Unis AS, Armenteros J, et al. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol. 2009;19:611-621.
27. Tohen M, Kryzhanovskaya L, Carlson G, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry. 2007;164:1547-1556.
28. Bonnot O, Inaoui R, Raffin-Viard M, et al. Children and adolescents with severe mental illness need Vitamin D supplementation regardless of disease or treatment J Child Adolesc Psychopharmacol. 2011;21:157-161.
29. Findling RL, Robb A, Nyilas M, et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry. 2008;165:1432-1441.
30. Marcus RN, Owen R, Kamen L, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009;48:1110-1119.
31. Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009;124:1533-1540.
32. Moreno C, Merchan-Naranjo J, Alvarez M, et al. Metabolic effects of second-generation antipsychotics in bipolar youth: Comparison with other psychotic and nonpsychotic diagnoses. Bipolar Disord. 2010;12:172-184.
33. McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: A randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164:1050-1060.
34. Findling RL, Johnson JL, McLellan J, et al. Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry. 2010;49:583-594.
35. Pavuluri MN, Henry DB, Findling RL, et al. Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder. Bipolar Disord. 2010;12:593-605.
36. Wozniak J, Mick E, Waxmonsky J, et al. Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder. J Child Adolesc Psychopharmacol. 2009;19:539-545.
37. Tramontina S, Zeni CP, Ketzer CR, et al. Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: A pilot randomized clinical trial. J Clin Psychiatry. 2009;70:756-764.
38. Delbello M. Research on the Effectiveness of Risperidone in Bipolar Disorder in Adolescents and Children (REACH): A double-blind, randomized, placebo-controlled study of the efficacy and safety of risperidone for the treatment of acute mania in bipolar I disorder. 2005. Available at: Http://download.veritasmedicine.com/PDF/CR003631-CSR.pdf. Accessed July 28, 2010.
39. Haas M, Eerdekens M, Kushner S, et al. Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: Double-blind study. Br J Psychiatry. 2009;194:158-164.
40. Biederman J, Mick E, Hammerness P, et al. Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biol Psychiatry. 2005;58:589-594.
41. Division of Psychiatry Products H. Statistical review and evaluation on ziprasidone NDA/serial no. 20-825 (SE5-032). 2009. Available at: Http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/ DevelopmentResources/UCM193492.pdf. Accessed July 28, 2010.
42. Kryzhanovskaya L, Schulz SC, McDougle C, et al. Olanzapine versus placebo in adolescents with schizophrenia: A 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48:60-70.
43. DelBello MP, Kowatch RA, Adler CM, et al. A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry. 2006;45:305-313.
44. DelBello MP, Chang K, Welge JA, et al. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord. 2009;11:483-493.
45. Rak IW. Seroquel\ (quetiapine fumarate) for treatment of pediatric patients with bipolar mania (10-17 years) or schizophrenia (13-17 years). 2009. Available at: Http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/ UCM177104.pdf. Accessed July 28, 2010.
46. Research Units in Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;(347):314-321.
47. Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004;114:e634-e641.
48. Aman MG, De Smedt G, Derivan A, et al. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry. 2002;159:1337-1346.
49. Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: A 12-week randomized and double-blind comparison. Biol Psychiatry. 2008;63:524-529.
50. Sporn AL, Bobb AJ, Gogtay N, et al. Hormonal correlates of clozapine-induced weight gain in psychotic children: An exploratory study. J Am Acad Child Adolesc Psychiatry. 2005;44:925-933.
51. Sallee FR, Kurlan R, Goetz CG, et al. Ziprasidone treatment of children and adolescents with Tourette's syndrome: A pilot study. J Am Acad Child Adolesc Psychiatry. 2000;39:292-299.
52. Snyder R, Turgay A, Aman M, et al. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry. 2002;41:1026-1036.
53. Kumra S, Frazier JA, Jacobsen LK, et al. Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry. 1996;53:1090-1097.
54. Saito E, Correll CU, Gallelli K, et al. A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. J Child Adolesc Psychopharmacol. 2004;14:350-358.
55. Findling RL, McNamara NK, Branicky LA, et al. A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry. 2000;39:509-516.
56. DelBello MP, Versavel M, Ice K, et al. Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder. J Child Adolesc Psychopharmacol. 2008;18:491-499.
57. Gaffney GR, Perry PJ, Lund BC, et al. Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. J Am Acad Child Adolesc Psychiatry. 2002;41:330-336.
58. Barzman DH, DelBello MP, Adler CM, et al. The efficacy and tolerability of quetiapine versus divalproex for the treatment of impulsivity and reactive aggression in adolescents with co-occurring bipolar disorder and disruptive behavior disorder(s). J Child Adolesc Psychopharmacol. 2006;16:665-670.
59. Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, et al. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry. 2001;62:239-248.
60. Shaw P, Sporn A, Gogtay N, et al. Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry. 2006;63:721-730.
61. Jensen JB, Kumra S, Leitten W, et al. A comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disorders. J Child Adolesc Psychopharmacol. 2008;18:317-326.
62. Mozes T, Ebert T, Michal SE, et al. An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia. J Child Adolesc Psychopharmacol. 2006;16:393-403.